MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- SUN PHARMA - TEVA PHARMA (Israel)
SUN PHARMA vs TEVA PHARMA (Israel) - Comparison Results
SUN PHARMA Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 SUN PHARMA  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-20 |
TEVA PHARMA Dec-13 |
SUN PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 484 | 3,123 | - | |
| Low | Rs | 315 | 2,713 | - | |
| Sales per share (Unadj.) | Rs | 136.9 | 1,792.3 | - | |
| Earnings per share (Unadj.) | Rs | 17.5 | 112.0 | - | |
| Cash flow per share (Unadj.) | Rs | 26.0 | 256.8 | - | |
| Dividends per share (Unadj.) | Rs | 4.00 | 98.01 | - | |
| Dividend yield (eoy) | % | 1.0 | 3.4 | 29.8% | |
| Book value per share (Unadj.) | Rs | 188.7 | 1,990.9 | - | |
| Shares outstanding (eoy) | m | 2,399.26 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.9 | 1.6 | 179.4% | |
| Avg P/E ratio | x | 22.9 | 26.1 | 87.9% | |
| P/CF ratio (eoy) | x | 15.4 | 11.4 | 135.3% | |
| Price / Book Value ratio | x | 2.1 | 1.5 | 144.5% | |
| Dividend payout | % | 22.9 | 87.5 | 26.2% | |
| Avg Mkt Cap | Rs m | 958,864 | 2,474,447 | 38.8% | |
| No. of employees | `000 | 17.8 | 44.9 | 39.5% | |
| Total wages/salary | Rs m | 63,624 | 0 | - | |
| Avg. sales/employee | Rs Th | 18,490.6 | 33,816.7 | 54.7% | |
| Avg. wages/employee | Rs Th | 3,582.6 | 0 | - | |
| Avg. net profit/employee | Rs Th | 2,357.6 | 2,112.5 | 111.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 328,375 | 1,519,893 | 21.6% | |
| Other income | Rs m | 6,360 | 0 | - | |
| Total revenues | Rs m | 334,735 | 1,519,893 | 22.0% | |
| Gross profit | Rs m | 69,898 | 416,224 | 16.8% | |
| Depreciation | Rs m | 20,528 | 122,854 | 16.7% | |
| Interest | Rs m | 3,027 | 29,853 | 10.1% | |
| Profit before tax | Rs m | 52,702 | 263,516 | 20.0% | |
| Minority Interest | Rs m | 0 | 1,197 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -2,606 | -172,984 | 1.5% | |
| Tax | Rs m | 8,228 | -3,217 | -255.7% | |
| Profit after tax | Rs m | 41,868 | 94,947 | 44.1% | |
| Gross profit margin | % | 21.3 | 27.4 | 77.7% | |
| Effective tax rate | % | 15.6 | -1.2 | -1,278.7% | |
| Net profit margin | % | 12.8 | 6.2 | 204.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 316,542 | 1,026,530 | 30.8% | |
| Current liabilities | Rs m | 157,064 | 895,221 | 17.5% | |
| Net working cap to sales | % | 48.6 | 8.6 | 562.1% | |
| Current ratio | x | 2.0 | 1.1 | 175.8% | |
| Inventory Days | Days | 88 | 91 | 96.4% | |
| Debtors Days | Days | 105 | 96 | 109.2% | |
| Net fixed assets | Rs m | 243,102 | 496,431 | 49.0% | |
| Share capital | Rs m | 2,399 | 3,741 | 64.1% | |
| Net worth | Rs m | 452,645 | 1,688,313 | 26.8% | |
| Long term debt | Rs m | 20,289 | 777,155 | 2.6% | |
| Total assets | Rs m | 682,525 | 3,473,444 | 19.6% | |
| Interest coverage | x | 18.4 | 9.8 | 187.3% | |
| Debt to equity ratio | x | 0 | 0.5 | 9.7% | |
| Sales to assets ratio | x | 0.5 | 0.4 | 110.0% | |
| Return on assets | % | 6.6 | 3.6 | 183.1% | |
| Return on equity | % | 9.2 | 5.6 | 164.5% | |
| Return on capital | % | 11.2 | 4.9 | 227.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 65,548 | 242,192 | 27.1% | |
| From Investments | Rs m | -25,888 | -85,819 | 30.2% | |
| From Financial Activity | Rs m | -57,151 | -290,526 | 19.7% | |
| Net Cashflow | Rs m | -13,857 | -134,152 | 10.3% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 74.82 Rs / USD
Compare SUN PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare SUN PHARMA With: FDC BIOCON WOCKHARDT DISHMAN PHARMA IPCA LABS
Today's Market
Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Related Views On News
SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)
Feb 1, 2021 | Updated on Feb 1, 2021For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)
Dec 11, 2020 | Updated on Dec 11, 2020Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)
Nov 6, 2020 | Updated on Nov 6, 2020For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
A Unique Sector for Short-Term Profits (Fast Profits Daily)
Apr 12, 2021This ignored sector could deliver big short-term profits.
More
